HOTH
Hoth Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.80
−2.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 6.4M | 5.9M | 3.2M | 3.5M | 4.9M |
| SG&A Expense | 6.7M | 6.4M | 5.0M | 4.2M | 6.1M |
| General & Admin Expense | 6.7M | 6.4M | 5.0M | 4.2M | 6.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (1.3M) | — | — | 0.00 |
| Total Operating Expenses | 13.2M | 11.1M | 8.2M | 7.7M | 11.1M |
| Cost and Expenses | 9.3M | 11.1M | 8.2M | 7.7M | 11.1M |
| Operating Income (EBIT) | (13.2M) | (11.1M) | (8.2M) | (7.7M) | (11.1M) |
| Non-Operating | |||||
| Interest Income | 307.00 | 680.00 | 27.7K | 51.8K | 6.4K |
| Interest Expense | — | — | — | — | 305.4K |
| Net Interest Income | 158.00 | 680.00 | 27.7K | 51.8K | (299.0K) |
| Other Non-Op Income/Expense | (152.2K) | (1.4M) | 27.1K | (153.1K) | (306.4K) |
| Non-Operating Income (excl Interest) | 152.3K | 1.4M | (27.1K) | 153.1K | 990.00 |
| EBT (Pre-Tax Income) | (13.3M) | (12.5M) | (8.2M) | (7.8M) | (11.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (13.3M) | (12.5M) | (8.2M) | (7.8M) | (11.4M) |
| Earnings from Cont. Ops | (13.3M) | (12.5M) | (8.2M) | (7.8M) | (11.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (13.3M) | (12.5M) | (8.2M) | (7.8M) | (11.4M) |
| Per Share | |||||
| Basic EPS | ($0.83) | ($0.90) | ($1.28) | ($2.30) | ($9.50) |
| Diluted EPS | ($0.83) | ($0.90) | ($1.28) | ($2.30) | ($9.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 20.5M | 13.8M | 6.4M | 3.4M | 1.2M |
| Diluted Shares Outstanding | 20.5M | 13.8M | 6.4M | 3.4M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (13.3M) | (12.5M) | 27.1K | (153.1K) | (990.00) |
| D&A | — | — | 8.2M | 7.7M | 11.1M |
| EBIT | (9.5M) | (12.5M) | (8.2M) | (7.8M) | (11.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026